Methimazole: Nursing Drug Guide, Agranulocytosis & Hold Rules
Healthcare medication guide: life-threatening agranulocytosis can present as fever or sore throat while hepatic injury may show as anorexia, pruritus, or right upper quadrant pain—hold promptly, obtain CBC with differential and liver tests, and coordinate antithyroid therapy for hyperthyroidism per prescribing information.
FDA labeling warns that agranulocytosis is a potentially serious adverse reaction of methimazole. Patients must report fever or sore throat immediately. The drug should be discontinued in the presence of agranulocytosis, aplastic anemia (pancytopenia), hepatitis, or exfoliative dermatitis, and bone marrow function should be monitored. About 10% of patients with untreated hyperthyroidism already have leukopenia—do not dismiss a low white count as “expected hyperthyroidism” without prescriber review when symptoms worsen on therapy.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, ask whether the patient has new fever, sore throat, mouth sores, or unexplained infection—hold methimazole and obtain a CBC with differential the same day. Hepatotoxicity can follow anorexia, pruritus, or right upper quadrant pain; discontinue promptly if transaminases exceed 3 times the upper limit of normal per labeling.
Most common brand names
Methimazole is the generic antithyroid drug used in many countries; thiamazole is an alternate name in some regions. In the United States, Tapazole is a historical brand name nurses may still see on home medication lists.
Tablets are commonly supplied as 5 mg and 10 mg oral strengths (scored). There is no routine IV methimazole product in standard U.S. labeling—verify oral orders and strength on every pass.
Why we give it — Indications
Methimazole inhibits thyroid hormone synthesis. Nurses use it in inpatient and outpatient settings to treat hyperthyroid states and to prepare patients for definitive therapy.
| Use | Detail |
|---|---|
| Graves disease / hyperthyroidism | Medical treatment of hyperthyroidism; long-term therapy may lead to remission per FDA labeling. |
| Preparation for definitive therapy | May ameliorate hyperthyroidism before subtotal thyroidectomy or radioactive iodine therapy when ordered. |
| When surgery is not advisable | Used when thyroidectomy is contraindicated or not advisable per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Methimazole inhibits synthesis of thyroid hormones. It does not inactivate thyroxine (T4) or triiodothyronine (T3) already stored in the thyroid or circulating in blood, and it does not block effectiveness of thyroid hormones given by mouth or injection. Clinical improvement in hyperthyroid symptoms therefore lags behind the start of therapy until hormone stores are depleted—typically weeks, not hours.
Dosing overview
Methimazole is administered orally. The total daily dose is usually divided into three doses at approximately 8-hour intervals per FDA labeling.
Pediatric dosing
Initially 0.4 mg/kg/day divided into three doses every 8 hours. Maintenance is approximately half the initial dose per labeling.
Renal impairment: Not specified in the reviewed prescribing information.
Hepatic impairment: Not specified in the reviewed prescribing information; use extreme caution—hepatotoxicity is a labeled warning.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy or prescriber for guidance if multiple doses are missed.
Before you give it — Safety check
Pretreatment checks
- Ask about fever, sore throat, mouth sores, skin eruptions, headache, or general malaise since the last dose
- Review recent complete blood count (CBC) with differential if symptoms suggest infection or if on high daily doses in older adults
- Screen for hepatic symptoms (jaundice, anorexia, pruritus, right upper quadrant pain) and baseline or trend liver function tests
- Confirm pregnancy status, breastfeeding plan, and concurrent drugs that cause myelosuppression
Contraindications
- Hypersensitivity to methimazole
- Nursing mothers—methimazole is excreted in milk and use is contraindicated in breastfeeding per FDA labeling
- Not specified in the reviewed prescribing information as an absolute contraindication for pregnancy; however, labeling warns of fetal harm (Pregnancy Category D) and congenital defect reports—therapy in pregnancy requires specialist decision-making
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Oral anticoagulants (warfarin) | Activity may be potentiated by anti–vitamin K effect attributed to methimazole | Monitor INR and bleeding; report bruising or hematuria |
| Beta-adrenergic blockers | Hyperthyroidism increases clearance; requirements may fall as patient becomes euthyroid | Monitor HR and BP; anticipate prescriber dose reduction of beta-blocker |
| Digitalis glycosides | Serum digitalis levels may increase when hyperthyroid patient becomes euthyroid | Watch for toxicity (nausea, vision changes, arrhythmia); notify prescriber |
| Theophylline | Clearance may decrease as euthyroid state is reached | Monitor for toxicity; coordinate dose changes with prescriber/pharmacy |
| Other myelosuppressive drugs | Increased risk of agranulocytosis | Reinforce infection reporting; verify CBC orders when clinically indicated |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral. Give in three divided doses about 8 hours apart when the total daily dose is divided per order.
- Verify strength (5 mg vs 10 mg) and total daily dose—high doses (≥40 mg/day) in patients older than 40 years are associated with agranulocytosis in labeling
- May give with or without food unless facility protocol specifies otherwise; consistency matters more than timing relative to meals
- Do not crush or split unless pharmacy approves for the specific tablet product
- Perform medication reconciliation at admission—home antithyroid doses are easily duplicated or omitted on transfer
Product labeling and package warnings state that methimazole may cause toxic reactions; if such reactions occur, discontinue the drug and maintain constant supervision of the patient.
Expected therapeutic response
- Gradual decrease in hyperthyroid symptoms (anxiety, tremor, heat intolerance, weight loss) over weeks
- Improving resting heart rate and fewer episodes of atrial fibrillation when hyperthyroidism drove tachyarrhythmia
- Rising TSH and falling free T4 on scheduled labs—an elevated TSH warrants dose decrease per labeling precautions
- Transition to maintenance dosing (often 5–15 mg/day) once euthyroid
Red flags — Stop and act
Hold methimazole and escalate immediately when infection or organ-toxicity cues appear—do not wait for routine rounding.
- New fever, sore throat, mouth ulcers, or flu-like illness—suspect agranulocytosis until CBC proves otherwise
- Exfoliative dermatitis or widespread serious skin reaction
- Jaundice, dark urine, severe right upper quadrant pain, or transaminases >3× upper limit of normal
- Signs of aplastic anemia or pancytopenia (unusual bleeding, severe fatigue, recurrent infections)
- Hypoglycemic confusion or loss of consciousness—insulin autoimmune syndrome with hypoglycemic coma is a rare labeled reaction
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Skin rash, urticaria, pruritus | Minor (more common) | Document extent; hold and notify if exfoliative or worsening |
| Nausea, vomiting, epigastric distress | Minor | Supportive care; differentiate from hepatitis if jaundice or RUQ pain |
| Agranulocytosis, granulocytopenia, thrombocytopenia | Major (less frequent) | Hold drug; STAT CBC with differential; infection precautions |
| Aplastic anemia (pancytopenia) | Major | Discontinue; hematology follow-up; reverse isolation per protocol |
| Hepatitis / jaundice | Major; jaundice may persist weeks after stop | Hold; LFTs; monitor for fulminant hepatic failure per labeling |
| Drug fever, lupus-like syndrome, hypoprothrombinemia | Major | Hold; notify prescriber; monitor PT if on anticoagulants |
| Insulin autoimmune syndrome (hypoglycemic coma) | Major (rare) | Check glucose; emergency pathway if altered mental status |
On a small screen, swipe or scroll sideways to see the full table.
About 10% of patients with untreated hyperthyroidism have leukopenia (WBC <4,000/mm³), often with relative granulopenia—compare trends on therapy rather than a single value alone.
Overdose, toxicity, and antidote
There is no specific antidote listed in FDA prescribing information. Management is supportive and guided by poison control or medical toxicology per facility protocol.
Signs and symptoms (labeling)
- Nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, edema
- Aplastic anemia or agranulocytosis may appear within hours to days
- Less frequent: hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, CNS stimulation or depression
Management
- Protect airway; support ventilation and perfusion; monitor vitals, blood gases, and electrolytes per protocol
- Monitor bone marrow function (CBC with differential)
- Consider activated charcoal if appropriate and not contraindicated—labeling notes charcoal may be more effective than emesis alone
- Forced diuresis, peritoneal dialysis, hemodialysis, and charcoal hemoperfusion have not been established as beneficial for methimazole overdose
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance when overdose or serious toxicity is suspected.
Look-alike / sound-alike and error prevention
- Methimazole vs metronidazole—similar syllables; verify drug name and indication (antithyroid vs antibiotic)
- Methimazole vs methotrexate—both immunomodulating in different contexts; read strength and frequency aloud
- 5 mg vs 10 mg tablets—both small white scored tablets in many products; use barcode scanning and independent double-check
- Total daily dose vs per-dose amount—orders such as “methimazole 10 mg TID” vs “10 mg daily” are high-risk; clarify with pharmacy
- Duplicate home and inpatient therapy—common on admission for Graves disease; reconcile with endocrine plan
- Confusion with levothyroxine—opposite effects; never substitute without prescriber order
No widely published ISMP LASA pair was identified for methimazole in the reviewed sources; still apply tall-man lettering and read-back for all antithyroid orders.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Infection card | Give wallet card: “Call immediately for fever or sore throat while on methimazole.” |
| Lab timing | When symptoms arise, CBC with differential is more urgent than waiting for routine morning labs |
| Hyperthyroid vitals | Trend HR and BP with free T4 and TSH—beta-blockers may mask incomplete control |
| Overtreatment cue | Rising TSH on labs may signal excessive antithyroid dose—prescriber may reduce methimazole per labeling |
| Pregnancy | Labeling warns of fetal goiter, cretinism, and rare congenital defects—obstetric and endocrine coordination required |
| Ask pharmacy when | Myelosuppressive co-therapy, pregnancy, breastfeeding questions, or transition to hypothyroid replacement after definitive therapy |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Patients >40 years on ≥40 mg/day | Labeling associates methimazole-induced agranulocytosis with doses of 40 mg or more in patients older than 40—heighten infection surveillance |
| Concurrent myelosuppressive drugs | Particular care per labeling; low threshold to obtain CBC when symptoms appear |
| Pre-existing leukopenia | Untreated hyperthyroidism may cause low WBC—interpret trends with symptoms on therapy |
| Pregnancy | Pregnancy Category D—can cause fetal harm, goiter, and rare congenital defects (e.g., aplasia cutis, esophageal atresia, choanal atresia per labeling). Specialist should weigh methimazole vs other agents. |
| Lactation | Contraindicated in nursing mothers per FDA labeling (excreted in milk). LactMed discusses expert use up to 20 mg daily with infant monitoring in selected cases—follow institutional policy. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Clinical infection cues: fever, sore throat, malaise, mouth sores at every contact
- CBC with differential when symptoms suggest agranulocytosis or per prescriber schedule
- Thyroid function (TSH, free T4)—elevated TSH warrants dose decrease per labeling
- Liver function (bilirubin, alkaline phosphatase, ALT, AST) if hepatic symptoms or transaminase elevation
- Prothrombin time when on oral anticoagulants—methimazole may cause hypoprothrombinemia
- Heart rate, rhythm, and hyperthyroid symptom trend
Document
- Patient education on fever/sore throat reporting and hold instructions
- Dose, strength, and time given; confirm three-times-daily division when ordered
- Hold events with prescriber notification and CBC or LFT results
- Thyroid lab trends and symptom response after dose changes
Patient teaching
- Take exactly as prescribed—often three times daily; do not change dose without prescriber approval
- Call immediately for fever, sore throat, mouth sores, or signs of infection—do not take the next dose until advised
- Report rash, yellowing skin or eyes, dark urine, abdominal pain, unusual bleeding, or severe fatigue
- Keep all laboratory appointments for blood and thyroid tests
- Inform all clinicians and pharmacists that you take methimazole before starting new medicines
- Pregnancy or breastfeeding plans require urgent prescriber discussion—do not stop or continue alone
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- New fever, sore throat, mouth ulcers, or suspected infection while on methimazole
- Confirmed or suspected agranulocytosis, granulocytopenia, thrombocytopenia, or aplastic anemia on CBC
- Clinical hepatitis, jaundice, or hepatic transaminases >3× upper limit of normal
- Exfoliative dermatitis or severe mucocutaneous reaction
- Hypoglycemia with altered mental status when insulin autoimmune syndrome is suspected
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Antithyroid therapy is often outpatient-led, but inpatient nurses must catch early myelosuppression and hepatic injury—the rare events that become emergencies when doses are continued after symptom onset.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and time—and verify 5 mg vs 10 mg strength
- Screen for fever, sore throat, or infection symptoms since last dose
- Review most recent CBC and LFT trends when available
- Confirm pregnancy/breastfeeding status and myelosuppressive co-medications on MAR
2. High-alert and safety badge
Serious toxicity risk — infection and marrow suppression surveillanceLabeling requires discontinuation for agranulocytosis, aplastic anemia, hepatitis, or exfoliative dermatitis. Treat fever on methimazole as a drug-safety event until proven otherwise.
3. Clinical workflow: hold and question rules
- Any febrile illness → hold dose, notify prescriber, obtain CBC with differential per protocol
- New jaundice or RUQ pain → hold, notify, obtain LFTs
- Order says “daily” but patient was previously on TID—clarify with pharmacy before administering
4. Critical teach-back questions
- “What symptoms mean you should call us before taking your next dose?” (Patient should name fever, sore throat, or signs of infection.)
- “Why do you need blood tests while on this medicine?” (Patient should link labs to checking thyroid control and detecting serious blood or liver reactions.)
5. Care coordination
Pharmacist: Dose verification, interaction review (warfarin, beta-blockers, theophylline), pregnancy/lactation counseling
Endocrinology / prescriber: Thyroid lab interpretation, transition to surgery or radioactive iodine, management of agranulocytosis or hepatitis
🧠 Quick mental checklist
- Does this patient have fever, sore throat, or infection symptoms today?
- Is the daily dose ≥40 mg in a patient older than 40?
- When were the last CBC and thyroid function tests—and what did they show?
- Any jaundice, RUQ pain, or new rash since therapy started?
- Is the patient pregnant, postpartum, or breastfeeding?
Methimazole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for methimazole agranulocytosis and hold rules using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), WBC trend interpretation, matrix urgency sorting, ordered response, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Methimazole 10 mg PO TID (30 mg/day) — 0800 and 1600 given; 2400 due
- Propranolol 20 mg PO TID — all doses given
- Home multivitamin held pending pharmacy review
- Patient age 52; Graves disease; started methimazole 3 weeks ago at 30 mg/day, increased to 30 mg/day total last week per endocrine
- Admission (3 weeks ago): WBC 6.8 ×10³/µL; ANC 4.2 ×10³/µL; AST 28 U/L; ALT 32 U/L
- Day 7: WBC 5.1 ×10³/µL; ANC 3.0 ×10³/µL; free T4 2.8 ng/dL (improving)
- Today (day 12, 1700): WBC 2.4 ×10³/µL; ANC 0.6 ×10³/µL; platelets 168 ×10³/µL; AST 34 U/L; ALT 38 U/L
- STAT CBC with differential repeated; blood cultures ordered
- Temp: 38.4 °C (101.1 °F) at 1500 — previously afebrile
- HR: 96–102 (down from 118 on admission); BP 118/72; RR 18; SpO₂ 97% on room air
- Reports mild sore throat and fatigue since noon
- 52-year-old with Graves disease; hyperthyroid symptoms improving; tremor decreased
- Patient states, “I thought a sore throat was from my allergies”—no prior allergy season documentation
- Oral inspection: erythematous pharynx without exudate
- Teaching gap: patient could not name fever/sore throat as reasons to hold methimazole
- Endocrine fellow aware of fever; awaiting repeat CBC before next dose
Answer key & rationale
Frequently asked questions
What symptoms should make a nurse hold methimazole?
Hold and contact the prescriber for fever, sore throat, or other infection symptoms; jaundice or right upper quadrant pain; exfoliative dermatitis; or suspected blood dyscrasia. FDA labeling requires discontinuation for agranulocytosis, aplastic anemia, hepatitis, or exfoliative dermatitis.
How is methimazole usually dosed in adults?
Oral methimazole is typically divided into three doses about 8 hours apart. Initial daily doses are 15 mg (mild), 30–40 mg (moderate), or 60 mg (severe) hyperthyroidism, with maintenance often 5–15 mg daily per labeling.
Can patients breastfeed while taking methimazole?
FDA labeling contraindicates use in nursing mothers because methimazole is excreted in breast milk. LactMed notes some experts use up to 20 mg daily with infant monitoring in selected cases—follow prescriber and institutional policy.
Is there an antidote for methimazole overdose?
No specific antidote is listed. Management is supportive with airway protection, monitoring, and poison control guidance. Dialysis has not been established as beneficial for methimazole overdose.
Why is fever dangerous on methimazole?
Fever with sore throat may be the first sign of agranulocytosis—a potentially life-threatening drop in neutrophils. Prompt CBC testing and drug discontinuation reduce sepsis risk.
References
-
U.S. National Library of Medicine. Methimazole tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74238d87-5f82-4a5e-a920-a9fc68115e91
-
Drugs and Lactation Database (LactMed). Methimazole. Bethesda (MD): National Institute of Child Health and Human Development; updated July 15, 2024.https://www.ncbi.nlm.nih.gov/books/NBK501024/
-
U.S. National Library of Medicine. Methimazole — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a682461.html
-
American Thyroid Association. Hyperthyroidism (overactive thyroid).https://www.thyroid.org/hyperthyroidism/
-
U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.